Tagged with M

China Dr Chengbin Wu, founder and CEO of EpimAb Biotherapeutics, introduces their exciting and proprietary bispecific antibody-generating platform, Fabs-In-Tandem Immunoglobulin (FIT-Ig®) and its ability to discover and generate novel and differentiated bispecific antibodies to meet unmet medical needs in China; shares the progress of their first program, EMB01, a EGFR-cMet bispecific…

Europe Bringing together insights from the heads of some of Europe’s most prominent mid-cap pharma firms. The leaders of Ipsen, Genmab, Pierre Fabre, Esteve and Servier outline the strategic directions in which their companies are turning and how they are planning to ensure a successful future.   David Meek, Ipsen David…

Egypt Ramez Mohsen, managing director at Janssen for Egypt, Jordan, Libya & Sudan, highlights how the company is driving real access to treatments in Egypt through collaboration with various stakeholders. He also assesses Egypt’s attractiveness for clinical trials and the initial results of the government’s prioritization of healthcare.   As the…

Opinion David H. Crean, managing director for Objective Capital Partners, highlights the progress that has been made over the past year in investments in medical cannabis and the outlook for 2019.     Due to ongoing research and studies, positive results are leading countries to reconsider the cannabis plant The cannabis industry…

Spain Jesús Cristóbal, CEO of Texpol, the market leader for single-use surgical dressings in Spain, describes the company’s beginnings and his role in its success. Cristóbal goes on to share his strategic vision as Texpol aims for international markets and a more diversified portfolio.   With the future evolution of European…

Egypt Ashraf Osman, president and CEO of AUG Pharma, explains how his company has become one of Egypt’s Top 30 pharmaceutical companies in less than four years of manufacturing, gives an insight into the branding strategy of an industry newcomer, and outlines the company’s export strategy.   In 2018 alone we…

France Inotrem is a French biotech company developing a novel approach to target inflammatory diseases based on the TREM-1 pathway. Its CEO, Dr Jean-Jacques Garaud explains why he decided to leave Big Pharma for biotech, lays out Inotrem’s recent milestones, and outlines his internationalization strategy.   The TREM-1 pathway can be…

Spain Marc Comas, managing director of Accord Healthcare Iberia, highlights the footprint of the company as the leading generics and biosimilars player in the Spanish hospital sector and how his early strategy when founding the affiliate has set them up for long-term success. Furthermore, he points out the dynamics of the…

Opinion Cerecin’s Charles Stacey looks at the large unmet medical need in diseases of the central nervous system (CNS), the looming socioeconomic burden that these diseases represent, and the innovative solutions needed to counter it.   45 percent of the patient population in neurology remains unserved – they either have no…

France Anne-Laurence Sabatini, vice president of Cluster France, Canada & Benelux at LEO Pharma, discusses the transformation of the company and how this has trickled down to her cluster. Furthermore, she talks about the strategic importance of France and the steps LEO Pharma is taking to be the preferred medical dermatology…

Korea SK Plasma is a blood plasma company that was spun off from SK Chemicals in 2015. Its CEO, Yun Ho Kim, offers his insights into the company’s vision to establish itself as a leader both domestically and globally, and how past preparation, such as the establishment of the Andong factory…

France Olivier Laureau, global president of Servier Group, outlines the impact of recent acquisitions, the significance of Servier’s recently-opened commercial subsidiary in the US, the ongoing importance of France to the global group, and Servier’s unique value proposition as a privately-owned R&D-focused company.   The acquisition of Shire products also allowed…